Literature DB >> 16230019

Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models.

Rona K Graham1, Elizabeth J Slow, Yu Deng, Nagat Bissada, Ge Lu, Jacqueline Pearson, Jacqueline Shehadeh, Blair R Leavitt, Lynn A Raymond, Michael R Hayden.   

Abstract

Huntington disease (HD) is a devastating neuropsychiatric disease caused by expansion of a trinucleotide repeat (CAG) in the HD gene. Neuropathological changes include the appearance of N-terminal huntingtin fragments, decreased brain weight and apoptotic neuronal loss in a select subset of neurons located in the striatum. There is still controversy over whether homozygosity for the mutation in HD is associated with a more severe phenotype. In humans, resolution of this issue has been complicated by the small number of homozygous patients and difficulty in the definition of reliable phenotypic endpoints. In order to definitively determine whether there is a correlation between phenotypic severity and expression levels of mutant huntingtin, we undertook a behavioral and neuropathological assessment of YAC128 mice with varying levels of mutant huntingtin. The results reveal a clear relationship between levels of mutant huntingtin and phenotype defined by earlier age of onset, more rapid progression, enhanced striatal volume loss, acceleration of nuclear huntingtin fragment accumulation and increased sensitivity to NMDAR-mediated excitotoxicity. These results provide clear evidence in vivo supporting a more severe phenotype associated with increased levels of mutant huntingtin as seen in homozygotes for HD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16230019     DOI: 10.1016/j.nbd.2005.08.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  34 in total

1.  Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.

Authors:  Cesar L Moreno; Michelle E Ehrlich; Charles V Mobbs
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

Review 2.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 3.  "Pre-symptomatic" Huntington's disease.

Authors:  Kevin Duff; Leigh J Beglinger; Jane S Paulsen
Journal:  Handb Clin Neurol       Date:  2008

4.  A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease.

Authors:  Kristina Bečanović; Anne Nørremølle; Scott J Neal; Chris Kay; Jennifer A Collins; David Arenillas; Tobias Lilja; Giulia Gaudenzi; Shiana Manoharan; Crystal N Doty; Jessalyn Beck; Nayana Lahiri; Elodie Portales-Casamar; Simon C Warby; Colúm Connolly; Rebecca A G De Souza; Sarah J Tabrizi; Ola Hermanson; Douglas R Langbehn; Michael R Hayden; Wyeth W Wasserman; Blair R Leavitt
Journal:  Nat Neurosci       Date:  2015-05-04       Impact factor: 24.884

Review 5.  Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease.

Authors:  Dagmar E Ehrnhoefer; Liza Sutton; Michael R Hayden
Journal:  Neuroscientist       Date:  2011-02-10       Impact factor: 7.519

Review 6.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

7.  Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex.

Authors:  Sybille Krauss; Nadine Griesche; Ewa Jastrzebska; Changwei Chen; Désiree Rutschow; Clemens Achmüller; Stephanie Dorn; Sylvia M Boesch; Maciej Lalowski; Erich Wanker; Rainer Schneider; Susann Schweiger
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice.

Authors:  Valeria Uribe; Bibiana K Y Wong; Rona K Graham; Corey L Cusack; Niels H Skotte; Mahmoud A Pouladi; Yuanyun Xie; Konstantin Feinberg; Yimiao Ou; Yingbin Ouyang; Yu Deng; Sonia Franciosi; Nagat Bissada; Amanda Spreeuw; Weining Zhang; Dagmar E Ehrnhoefer; Kuljeet Vaid; Freda D Miller; Mohanish Deshmukh; David Howland; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2012-01-18       Impact factor: 6.150

9.  An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.

Authors:  Rodrigo A Fuentealba; Jayne Marasa; Marc I Diamond; David Piwnica-Worms; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2011-11-03       Impact factor: 6.150

10.  Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

Authors:  Ian H Kratter; Hengameh Zahed; Alice Lau; Andrey S Tsvetkov; Aaron C Daub; Kurt F Weiberth; Xiaofeng Gu; Frédéric Saudou; Sandrine Humbert; X William Yang; Alex Osmand; Joan S Steffan; Eliezer Masliah; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.